Yoshida-gun, Japan Clinical Trials

A listing of Yoshida-gun, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack …

angiography
troponin
clopidogrel
ck-mb
antiplatelet therapy
Fukui Prefectural Hospital
 (5.1 away) Contact site
  • 57 views
  • 09 Jun, 2021
  • +192 other locations
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. ABBV-154 is …

antirheumatics
stiffness
methotrexate
rheumatism
Sugimoto rheumatology and internal medicine clinic /ID# 229495
 (6.9 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +255 other locations
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels of JNJ-53718678 in children greater than or equal to 28 days and less than or equal to 3 years of age with respiratory syncytial virus (RSV) disease …

respiratory tract infection
antivirals
jnj-53718678
Fukui-ken Saiseikai Hospital
 (4.7 away) Contact site
  • 93 views
  • 13 Jun, 2021
  • +322 other locations
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

Fukui-ken Saiseikai Hospital
 (4.7 away) Contact site
  • 212 views
  • 13 Jun, 2021
  • +171 other locations
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

hepatic fibrosis
steatohepatitis
fibrosis
Fukui-Ken Saiseikai Hospital
 (4.7 away) Contact site
  • 72 views
  • 10 Jun, 2021
  • +317 other locations
Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants on stable nucleos(t)ide analogue (NA) therapy, and whether virologic response can …

hepatitis
telbivudine
GSK Investigational Site
 (5.2 away) Contact site
  • 0 views
  • 22 May, 2021
  • +36 other locations
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the …

Fukui-ken Saiseikai Hospital ( Site 1410)
 (4.7 away) Contact site
  • 0 views
  • 15 Jun, 2021
  • +79 other locations
Open-Label Study of Parsaclisib in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma

lymphoma
follicular lymphoma
University of Fukui Hospital
 (3.2 away) Contact site
  • 0 views
  • 04 Apr, 2021
  • +8 other locations
A Study of Guselkumab in Participants With Systemic Sclerosis

The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

raynaud's syndrome
rheumatism
raynaud's phenomenon
MRSS
carbon monoxide
University of Fukui Hospital
 (3.8 away) Contact site
  • 0 views
  • 23 May, 2021
  • +3 other locations